Human SOCS4 activation kit by CRISPRa

CAT#: GA114789

SOCS4 CRISPRa kit - CRISPR gene activation of human suppressor of cytokine signaling 4



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
SOCS4 mouse monoclonal antibody,clone OTI5H9
    • 100 ul

CNY 1,999.00
CNY 2,700.00


SOCS4 (Myc-DDK-tagged)-Human suppressor of cytokine signaling 4 (SOCS4), transcript variant 1
    • 10 ug

CNY 3,656.00
CNY 3,990.00


SOCS4 mouse monoclonal antibody,clone OTI5H9
    • 30 ul

CNY 800.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol SOCS4
Locus ID 122809
Kit Components

GA114789G1, SOCS4 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA114789G2, SOCS4 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA114789G3, SOCS4 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_080867, NM_199421
Synonyms SOCS7
Summary The protein encoded by this gene contains a SH2 domain and a SOCS BOX domain. The protein thus belongs to the suppressor of cytokine signaling (SOCS), also known as STAT-induced STAT inhibitor (SSI), protein family. SOCS family members are known to be cytokine-inducible negative regulators of cytokine signaling. Two alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...